Emerging evidence suggests that statins may decrease the risk of cancers. However, available evidence on non-muscle invasive bladder cancer is conflicting. To quantify the association between statin use and risk of non-muscle invasive bladder cancer, we performed a detailed meta-analysis of published studies regarding this subject.

We conducted a meta-analysis with data from all studies that compared the hazard ratio of overall survival, cancer-specific survival, progression-free survival , and cystectomy rate in patients with non muscle invasive bladder cancer who receive statin therapy. Studies were selected from the PubMed, Embase, and Cochrane library databases from their inception to March 31, 2025.

A total of 9 trials with 20000 participants were included. Pooled result showed statin therapy was not associated with higher overall survival(HR = 0.96, 95% CI: 0.82–1.12), cancer-specific survival, (HR = 0.90, 95% CI: 0.35–2.32) progression-free survival (HR = 1.00, 95% CI: 0.58–1.72)compared with no statin. In addition, we found no significant association between statin use and the risk of cystectomy (HR = 1.49, 95% CI: 0.22–10.22)

The findings of this meta-analysis suggested that statin use was not associated with improved overall survival, cancer-specific survival, progression-free survival , and cystectomy rate in patients with non muscle invasive bladder cancer. More studies, especially RCTs, are needed to confirm this association.